RF ablation received approval for EFS to treat a.fib

October 2022

Tau Medical Inc.

Tau Medical announced receiving the approval of the Korean Ministry of Food and Drug Safety (MFDS) for clinical study of its RF ablation catheter, TIRA for VoM (Vein of Marshall) ablation to treat a.fib (atrial fibrillation).


The study is using TIRA to ablate the Vein of Marshall and to check whether the ablation is safe and effective to treat the atrial fibrillation. Although alcohol ablation of VoM is used to treat a.fib as one of treatments, it’s not that much target specific and Tau Medical’s TIRA will be tested for more target specific way for ablating a.fib.


The study will be done with 7 patients in Seoul Asan Medical Center and Pusan National University Yangsan Hospital.




The TIRA, Transcatheter Interventional RF Ablation, is a catheter with electrode tips that delivers RF (Radio Frequency) energy to target tissue and ablates the tissue through heating. The device consists of electrode catheter and RF generator. Since the catheter can be delivered over the guide wire, it can be applied to various areas, and since it contains a cooling mechanism inside the catheter, it can show enough ablation effect without charring the tissue. Tau is also testing the TIRA for HoCM (Hypertrophic Obstructive Cardiomyopathy) and peripheral lung cancer as well as VoM ablation.


[Tau Medical Inc.] 

Tau Medical is developing trans-catheter devices for structural heart diseases like MR (Mitral valve regurgitation), TR (Tricuspid valve regurgitation) and HoCM (Hypertrophic Obstructive Cardiomyopathy). Tau’s Cerclage MR is well known as an innovative annuloplasty treatment for MR and enlarged LV reshaping, and is now under clinical study. 



© Tau-Medical Inc. All Rights Reserved.